Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Helio S Sader

Showing results (81-90 of 420) with videos related to

Pageof 42
Sort By:
Antimicrobial Agents and Chemotherapy|September 19, 2018
Antimicrobial Susceptibility of Pseudomonas aeruginosa to Ceftazidime-Avibactam, Ceftolozane-Tazobactam, Piperacillin-Tazobactam, and Meropenem Stratified by U.S. Census Divisions: Results from the 2017 INFORM ProgramHelio S Sader, Robert K Flamm, Cecilia G Carvalhaes, et al.
Antimicrobial Agents and Chemotherapy|February 26, 2020
Antimicrobial Activity of Ceftolozane-Tazobactam and Comparators against Clinical Isolates of Haemophilus influenzae from the United States and EuropeHelio S Sader, Cecilia G Carvalhaes, Leonard R Duncan, et al.
Diagnostic Microbiology and Infectious Disease|January 12, 2020
Comparison of ceftazidime-avibactam and ceftolozane-tazobactam in vitro activities when tested against gram-negative bacteria isolated from patients hospitalized with pneumonia in United States medical centers (2017-2018)Helio S Sader, Robert K Flamm, Cecilia G Carvalhaes, et al.
Diagnostic Microbiology and Infectious Disease|November 1, 2005
Susceptibility patterns for amoxicillin/clavulanate tests mimicking the licensed formulations and pharmacokinetic relationships: do the MIC obtained with 2:1 ratio testing accurately reflect activity against beta-lactamase-producing strains of Haemophilus influenzae and Moraxella catarrhalis?Sudha Pottumarthy, Helio S Sader, Thomas R Fritsche, et al.
Journal of Chemotherapy (Florence, Italy)|March 8, 2019
Distribution of main Gram-positive pathogens causing bloodstream infections in United States and European hospitals during the SENTRY Antimicrobial Surveillance Program (2010-2016): concomitant analysis of oritavancin in vitro activityRodrigo E Mendes, Helio S Sader, Mariana Castanheira, et al.
Antimicrobial Agents and Chemotherapy|January 11, 2017
Pseudomonas aeruginosa Antimicrobial Susceptibility Results from Four Years (2012 to 2015) of the International Network for Optimal Resistance Monitoring Program in the United StatesHelio S Sader, Michael D Huband, Mariana Castanheira, et al.
Antimicrobial Agents and Chemotherapy|January 13, 2025
Ceftobiprole activity against multidrug-resistant <i>Staphylococcus aureus</i> clinical isolates collected in the United States from 2016 through 2022Helio S Sader, Jennifer I Smart, Rodrigo E Mendes, et al.
Antibiotics (Basel, Switzerland)|April 27, 2026
In Vitro Antimicrobial Activity of Ceftobiprole and Comparator Agents Against <i>Streptococcus pneumoniae</i> Responsible for Lower Respiratory Tract Infections in the United States (2016-2020), Including Resistant Subsets and Select SerotypesHelio S Sader, Mariana Castanheira, Mark E Jones, et al.
Antimicrobial Agents and Chemotherapy|April 27, 2016
Antimicrobial Activities of Ceftazidime-Avibactam and Comparator Agents against Gram-Negative Organisms Isolated from Patients with Urinary Tract Infections in U.S. Medical Centers, 2012 to 2014Helio S Sader, Mariana Castanheira, Robert K Flamm, et al.
Antimicrobial Agents and Chemotherapy|May 25, 2016
Changes in the Frequencies of β-Lactamase Genes among Enterobacteriaceae Isolates in U.S. Hospitals, 2012 to 2014: Activity of Ceftazidime-Avibactam Tested against β-Lactamase-Producing IsolatesMariana Castanheira, Rodrigo E Mendes, Ronald N Jones, et al.
Pageof 42

Showing results (81-90 of 420) with videos related to

Sort By:
Pageof 42
Antimicrobial Agents and Chemotherapy|September 19, 2018
Antimicrobial Susceptibility of Pseudomonas aeruginosa to Ceftazidime-Avibactam, Ceftolozane-Tazobactam, Piperacillin-Tazobactam, and Meropenem Stratified by U.S. Census Divisions: Results from the 2017 INFORM ProgramHelio S Sader, Robert K Flamm, Cecilia G Carvalhaes, et al.
Antimicrobial Agents and Chemotherapy|February 26, 2020
Antimicrobial Activity of Ceftolozane-Tazobactam and Comparators against Clinical Isolates of Haemophilus influenzae from the United States and EuropeHelio S Sader, Cecilia G Carvalhaes, Leonard R Duncan, et al.
Diagnostic Microbiology and Infectious Disease|January 12, 2020
Comparison of ceftazidime-avibactam and ceftolozane-tazobactam in vitro activities when tested against gram-negative bacteria isolated from patients hospitalized with pneumonia in United States medical centers (2017-2018)Helio S Sader, Robert K Flamm, Cecilia G Carvalhaes, et al.
Diagnostic Microbiology and Infectious Disease|November 1, 2005
Susceptibility patterns for amoxicillin/clavulanate tests mimicking the licensed formulations and pharmacokinetic relationships: do the MIC obtained with 2:1 ratio testing accurately reflect activity against beta-lactamase-producing strains of Haemophilus influenzae and Moraxella catarrhalis?Sudha Pottumarthy, Helio S Sader, Thomas R Fritsche, et al.
Journal of Chemotherapy (Florence, Italy)|March 8, 2019
Distribution of main Gram-positive pathogens causing bloodstream infections in United States and European hospitals during the SENTRY Antimicrobial Surveillance Program (2010-2016): concomitant analysis of oritavancin in vitro activityRodrigo E Mendes, Helio S Sader, Mariana Castanheira, et al.
Antimicrobial Agents and Chemotherapy|January 11, 2017
Pseudomonas aeruginosa Antimicrobial Susceptibility Results from Four Years (2012 to 2015) of the International Network for Optimal Resistance Monitoring Program in the United StatesHelio S Sader, Michael D Huband, Mariana Castanheira, et al.
Antimicrobial Agents and Chemotherapy|January 13, 2025
Ceftobiprole activity against multidrug-resistant <i>Staphylococcus aureus</i> clinical isolates collected in the United States from 2016 through 2022Helio S Sader, Jennifer I Smart, Rodrigo E Mendes, et al.
Antibiotics (Basel, Switzerland)|April 27, 2026
In Vitro Antimicrobial Activity of Ceftobiprole and Comparator Agents Against <i>Streptococcus pneumoniae</i> Responsible for Lower Respiratory Tract Infections in the United States (2016-2020), Including Resistant Subsets and Select SerotypesHelio S Sader, Mariana Castanheira, Mark E Jones, et al.
Antimicrobial Agents and Chemotherapy|April 27, 2016
Antimicrobial Activities of Ceftazidime-Avibactam and Comparator Agents against Gram-Negative Organisms Isolated from Patients with Urinary Tract Infections in U.S. Medical Centers, 2012 to 2014Helio S Sader, Mariana Castanheira, Robert K Flamm, et al.
Antimicrobial Agents and Chemotherapy|May 25, 2016
Changes in the Frequencies of β-Lactamase Genes among Enterobacteriaceae Isolates in U.S. Hospitals, 2012 to 2014: Activity of Ceftazidime-Avibactam Tested against β-Lactamase-Producing IsolatesMariana Castanheira, Rodrigo E Mendes, Ronald N Jones, et al.
Pageof 42